Skip to main content
. Author manuscript; available in PMC: 2012 Sep 5.
Published in final edited form as: Int J Neuropsychopharmacol. 2010 Sep 29;14(1):131–142. doi: 10.1017/S146114571000101X

Fig. 1.

Fig. 1

Risk for discontinuation due to adverse events relative to placebo during quetiapine-XR ≥300 mg/d treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder. NNTH, Number needed to treat to harm.